| Literature DB >> 28989646 |
Jing Yang1,2, Xueli Zhang1,3, Yiying Zhu4, Emily Lenczowski5, Yanli Tian1,6, Jian Yang1,3, Can Zhang7, Markus Hardt4, Chunhua Qiao2, Rudolph E Tanzi7, Anna Moore1, Hui Ye5, Chongzhao Ran1.
Abstract
The biological fate of amyloid beta (Aβ) species is a fundamental question in Alzheimer's disease (Entities:
Year: 2017 PMID: 28989646 PMCID: PMC5627602 DOI: 10.1039/c7sc01787a
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Fig. 1Degradation of Aβ induced by Cu(ii) and Vc. (a) SDS-PAGE of FAM-Aβ42 with H2O2, Cu(ii), and Cu(ii)/Vc (1 : 10). Two fast migrating bands A and B can be clearly seen. (b) Western blotting with 6E10 antibody for Aβ42, Aβ42/Cu(ii)/Vc (1 : 10), Aβ6 and Aβ12. Aβ6 and Aβ12 cannot be visualized with the antibody.
Fig. 2Identification of the degraded fragments of native Aβ42 using nanoLC-MS/MS. (a) Relative intensities of the sequences of interest in 50% (R 50%, black bars) and 100% (R 100%, red bars) of H2 18O buffer. The calculation was based on XICR (R 50% or R 100% = XICRCu/XICRControl). Left insert: zoomed in image of the red circle; middle insert: XICR of the whole sequence of native Aβ42; right insert: zoomed in image of the black circle. (b) Skyline of nano-LC (left panel, red: normal MS; blue: 18O incorporated) and MS (right panel: purple) of a representative degraded fragment, Aβ6 (DAEFRH), in 0% (control), 50% and 100% H2 18O buffer. Note that the MS patterns changed with the increasing H2 18O content. (c) MS/MS of the representative degraded fragment Aβ6 in (b).
Fig. 3(a) SDS-PAGE of FAM-Aβ42 with different ratios of Cu(ii)/Vc (1 : 1, 1 : 5, 1 : 10 and 1 : 20). (b) Quantitative analysis of the cleaved bands for each condition in (a) (n = 3). (c) SDS-PAGE of FAM-Aβ42 with Cu(ii)/Vc, Zn(ii), Fe(iii), Zn(ii)/Vc, and Fe(iii)/Vc. (d) SDS-PAGE of FAM-Aβ42 with CuSO4 and different anti-oxidants, including Vc, vitamin E (Ve), curcumin, NE, dopamine, and resrevatrol. FAM-Aβ42 (Lane 1); FAM-Aβ42/Cu(ii) 1 : 1 (Lane 2); FAM-Aβ42/Cu(ii)/anti-oxidants 1 : 1 : 20 (Lanes 3–8). (e) Quantitative analysis of the cleaved bands for each condition in (d) (n = 3). (f) Quantitative analysis of the cleaved bands for each condition in (g) (n = 3). (g) SDS-PAGE of FAM-Aβ42 with the combination of Cu(ii)/Vc and anti-aggregating drug clioquninol (CQ). FAM-Aβ42 (Lane 1); FAM-Aβ42/Cu(ii)/Vc 1 : 1 : 20 (Lane 2); Lanes 3–8: FAM-Aβ42/Cu(ii)/Vc/CQ = 1 : 1 : 20 : 0.1 (Ln3), 0.5 (Ln4), 1.0 (Ln5), 2.0 (Ln6), 5.0 (Ln7), 10.0 (Ln8).
Fig. 4The degradation of the native Aβ40 aggregates induced by Cu(ii)/Vc. (a) TEM image of the Aβ40 aggregates before degradation (top) and after degradation (bottom). Right panel: high magnificent image. (b) Thioflavin T fluorescence testing with the Aβ40 aggregates before degradation (red) and after degradation (blue). (c) Zoomed in image of the debris of a degraded fibril.
Fig. 5(a) fEPSP recording of mouse brain slices treated with the vehicle (left), Aβ42 (middle), and Aβ42/Cu(ii)/Vc (right). (b) Quantification of the fEPSP in (a). (c) Quantification of the PPF ratio of the vehicle, Aβ42, and Aβ42/Cu(ii)/Vc.